BACKGROUND: Peripheral stem cell collections can be challenging in the pediatric population and respective experience is limited. Since February 2015 our institution is utilizing the new Spectra Optia (Optia) apheresis device, which has replaced the former COBE Spectra (COBE) device. As a quality initiative we collected and compared collection efficiency (CE2) and other collection variables between the two devices.
RESULTS: Forty-one collection procedures performed on 29 pediatric patients with the Optia device were compared to 41 collections performed on 27 patients with the COBE device. The TBVs through the Optia device were significantly smaller than the COBE (3.9 6 0.2 3 TBV vs. 5.5 6 0.1 3 TBV, respectively; p < 0.001), requiring significantly less anticoagulant and providing similar amounts of stem cells while collection times were significantly shorter (mean, 238 6 9 min vs. 264 6 9 min, respectively; p < 0.05). Collections on the Optia caused significantly smaller reductions of plasma calcium and magnesium. No significant side effects attributed to the procedure were noted.
CONCLUSION: Stem cell apheresis with the Optia device in children is safe and feasible with smaller blood volumes with shorter collection times.
A utologous stem cell transplantation (ASCT) is an integral part of the treatment of various pediatric cancers including high-risk neuroblastoma, various brain tumors, retinoblastoma, bone and soft tissue sarcomas, and lymphomas. [1] [2] [3] [4] [5] The initial part of the ASCT process requires collection of stem cells, which can be challenging in the pediatric population, especially for low-weight patients such as babies and toddlers, who are more prone to hemodynamic influences of fluid shifts due to the circulating blood volumes and to the exposure to anticoagulants and who may have more difficulty with the prolonged duration of the collection procedure. [6] [7] [8] Our medical center performs approximately 50 ASCTs per year for pediatric patients. In February 2015 our institution introduced the novel Spectra Optia MNC (Optia) apheresis device for the collection of mobilized peripheral stem cells, which has eventually replaced the former COBE Spectra (COBE) device (both from TerumoBCT).
Both devices use centrifugation for blood separation, but have some major mechanical differences. The Optia device has a more advanced automated interface management system and a secondary collection chamber that separates the mononuclear cells from the platelets (PLTs). 9 Optia uses feedback it receives from the automated interface management system to control the interface position, which is essential to remove the desired blood components, in conjunction with the user-dependent function, known as the collection preference. The collection preference defines the yield versus purity of the collection. This function of the Optia device provides a fine control of the depth of the collection into the buffy coat. The COBE device requires intermittent manual interface control and repositioning by the operator, based on the product color and aspect of the product aspired through the collect port, which renders stem cell collections more user dependent and in essence more difficult. The published experience with the Optia device in children is very limited. As part of our internal validation process we therefore compared the two apheresis devices in pediatric patients with malignancies in regard to collection efficiency (CE2), procedure time, side effects, and other relevant collection variables.
MATERIALS AND METHODS
This study was performed as part of a validation process while utilizing the new Optia apheresis device for stem cell collections in our center. Our main hypothesis was that the new Optia device is as efficient and safe as the former COBE device for autologous stem cell collections for pediatric cancer patients. We retrospectively collected clinical, laboratory, and technical collection data from stem cell collections with the Optia device and compared them to a similar historical group of consecutive collections done with the COBE device. The study received institutional ethics approval as a QI project.
The collected demographic data included patient sex, age, and weight at the time of collection; patient-estimated blood volume (calculated as weight 3 75); primary disease; and number of collection procedures per patient. Laboratory data included precollection peripheral CD341 cell counts and total CD341 cells collected in the product measured by the flow laboratory, complete blood count, serum ionized calcium (iCa) and magnesium (Mg) before and after collection. We calculated decrease in iCa, Mg, and PLTs in percent, negative percentages indicating a postcollection increase. All electrolytes were measured using a portable blood analyzer (iSTAT MN 300-G, Abbott; and Vitros 4600, Ortho Clinical Diagnostics); all complete blood counts were measured using iSTAT (same as mentioned) and an automated hematology analyzer (Sapphire, Cell-Dyn). CD341 cell viability was defined as percentage of viable CD341 cells by flow cytometry utilizing 7-aminoactinomycin D, a nucleic acid stain that does not cross the intact cell membrane. Adverse events were defined as any untoward medical occurrence associated with the collection procedure that induced clinical signs or symptoms that were considered clinically meaningful or require therapy. Technical collection data included total blood volumes processed (TBVs), acid citrate dextrose (ACD) exposure defined as the total volume of ACD processed through the machine during the collection procedure per kilogram of patient body weight (BW), and collection times for each procedure.
Our primary outcome was the calculated CE2 and collection ratios (CRs) for both machines. The CE2 of CD341 cells was calculated as the number of CD341 cells collected in the product bag divided by the total number of CD341 cells going through the apheresis device. The collected CD341 cells in the product were calculated by multiplying the CD341 cell count/kg by the patient BW. The total CD341 cells processed through the machine were calculated by multiplying the precollection peripheral CD341 cell count by the total processed blood volume (TPV) after reduction of the ACD volume, assuming stable CD341 levels in the circulation throughout the apheresis time. 10, 11 The CE2 calculation was calculated using the formula CE2 % ð Þ 5 product CD341 cells=kg
The CR was calculated as the total number of collected CD341 cells relative to the BW over the concentration of CD341 cells in the circulation, 12 via the formula
Secondary outcomes included number of collection procedures needed per patient to reach the target CD341 count goal; the collection yield (product CD341/kg); number of TBVs per collection; collection run times; product white blood cell (WBC) count and cell viability; patient %PLT, %iCa, and %Mg drops after collection; and other side effects attributed to the collection procedure. For further analysis patients were also divided into three different weight subgroups as follows: low weight (<15 kg), medium weight (15-30 kg), and heavy weight (>30 kg). Poor mobilizers were defined as less than 20 3 10 6 CD341 cells/L before collection and good mobilizers with more than 20 3 10 6 CD341 cells/L.
Description of the ASCT collection procedure
For stem cell mobilization, all patients were treated with high-dose subcutaneous granulocyte-colony-stimulating factor (G-CSF; 16 mg/kg per dose) for 3 consecutive days before the collection date. Patients who failed to reach their target CD341 with a first collection were treated with a double dose of G-CSF and a second collection was done the following day. Mobilization with plerixafor was usually considered for patients who failed a second collection at the discretion of the treating physician.
The targeted collection CD341 cell dose was dependent on the patient's disease and the specific protocol the patient was treated on as some protocols require more than one autologous transplant. For each planned transplant including one backup we aimed for a target of 2 3 10 6 to 5 3 10 6 CD341 cells/kg. For patients with neuroblastoma an additional 2 3 10 6 to 4 3 10 6 CD341/kg cells were collected for potential stem cell rescue after MIBG treatment.
A central venous line was inserted before the collection. The central venous line was required to accommodate a minimal blood flow of at least 10 mL/min (8) (9) (10) (11) (12) (13) (14) . Maximal tolerated flow rate was set as double the patient weight to a maximum of 85 mL/min; however, actual flow rate was restricted by the anticoagulant infusion rate variable which the machine was set on.
The patients had to meet standard clinical criteria for collection including hemoglobin level of more than 70 g/L, PLT count of more than 50 3 10 9 /L, TCO 2 of less than 30 mmol/L, potassium between 3 and 5.5 mmol/L, Mg of more than 0.5 mmol/L, and phosphate of more than 1 mmol/L (>2 years) or more than 0.7 mmol/L (<2 years). Blood products and electrolytes were given before the procedure if needed. iCa was measured and managed by a calcium gluconate infusion diluted 1:1 with normal saline, titrated to the patient's iCa and inlet flow, according to a standard table. During the procedure the patients were monitored with a cardiac monitor and a 1:1 nurse-per-patient ratio.
Machine settings
The machine was set for an anticoagulant infusion rate of up to 2.5 mL/min per TBV for patients less than 30 kg and up to 1.2 mL/min for patients more than 30 kg. Citrate was used as the anticoagulant for all collections, regardless of patient size, as per the manufacturer's recommendation. Anticoagulant ratio was set based on the patient PLT count before treatment; a ratio of 1:12 for patients with PLT count of more than 50 3 10 9 /L and a ratio of 1:15 for patients with a PLT count of less than 50 3 10 9 /L. With the COBE machine the volume of plasma collection for the stem cell product suspension was programed manually as opposed to automated concurrent plasma collection of 100 mL plasma for each collection with the Optia device. The chamber flush was set to 16 mL and chamber chase 4 mL according to the manufacturer's recommendations to optimize emptying of cells from the chamber. Blood priming was done for extracorporeal volume that exceeded TBVs of 15% in the Optia and 10% in the COBE. Extracorporeal volume for the Optia was 242 mL, and for COBE, approximately 300 mL.
Statistical analysis
Statistical analysis was performed with the computer software (Excel, Microsoft Corp.; and R, https://www.r-project.org/). The results are presented as mean 6 standard error of mean (SEM) unless specified otherwise. The collected variables of the two groups were compared by utilizing two sided t test, chi-square test, and Fisher test, as applicable. A p value of less than 0.05 was considered significant.
RESULTS
During the period between February 2015 and January 2016, a total of 41 stem cell collection procedures were performed on 29 pediatric patients with the new Optia device in our center and we compared them with an historical group of 41 consecutive collections performed on 27 patients with the COBE device, which were done between October 2013 and January 2015. The mean age of all the 56 patients was 5.38 years (range, 0.4-16.4 years) and mean weight was 23.1 kg (range, 7-87 kg). There was no significant difference between the two groups in respect to the age, weight, and sex ( Table 1) .
The underlying diseases of the patients were similar between the groups with neuroblastoma being the most prevalent diagnosis in both groups: 12 patients (44%) with neuroblastoma in the COBE group and 15 patients (51%) in the Optia group. Medulloblastoma was the second most prevalent diagnosis, six patients (22%) in the COBE group and seven patients (24%) in the Optia group (Table 1) .
The two groups had comparable peripheral precollection CD341 cell counts and similar end product CD341 cell counts (Table 2) . However, processed blood volumes were significantly lower in the Optia group compared to the COBE group, which resulted in significantly lower ACD exposure during the procedure in the Optia group (p 5 0.02) and significantly shorter collection times on the Optia (p 5 0.043, Table 2 ). The mean calculated CE2 of the Optia group was higher than the COBE group but did not reach significance (Optia 61.25 6 4.4% vs. COBE 53.36 6 4.28%, p 5 0.197; Fig. 1A ). The mean calculated CR was significantly lower in the Optia group (Fig. 1B) . The two groups had comparable numbers of collections required per patient to reach the target CD341 collected cells, with most patients requiring only a single procedure in both groups: 22 patients in the COBE group versus 21 patients in the Optia (Table 1 ). The product volumes of the Optia group were larger, with significantly lesser amounts of WBCs per liter (p < 0.001). There was no significant difference with respect to the end product cell viability between the groups ( Table 2) .
The collection procedure was tolerated well in both groups with no major side effects noted. There was no significant difference with regards to the mean percentage of PLT reduction after collection between the groups. However, the Optia group had significantly less reduction of plasma iCa and Mg after the procedure then the COBE group (Table 2) .
When dividing the patients to three weight subgroups, there were a total of 20 low-weight (<15 kg) patients, nine collected with the COBE and 11 with the Optia. Table 3 shows the clinical and collection data of the low-weight patients. Run times were shorter in the medium (15-30 kg) and heavy (>30 kg) weight patients and similar in the low-weight patients ( Fig. 2A) . Mg and iCa depletions were less pronounced on the Optia, most significantly in the low-weight subgroup.
When dividing the patients into subgroups according to the precollection CD341 peripheral counts to poor mobilizers with less than 20 3 10 6 CD341 cells/L and good mobilizers with more than 20 3 10 6 CD341 cells/L, the subgroup of poor mobilizers consisted of 17 collections from five patients on the COBE and 12 collections from six patients on the Optia (Table 4 ). The underlying diseases of the poor mobilizers were variable: three patients with neuroblastoma, three with medulloblastoma, two with retinoblastoma, one with histiocytic sarcoma, one with acute myeloid leukemia, and one with Hodgkin's lymphoma. The CE2 was higher in the Optia subgroup but did not reach significance. All patients required at least two collections; however, no patient in the Optia subgroup required more than three collections (mean, 2.3 collections/patient), whereas three patients required four collections in the COBE subgroup (mean, 3.4 collections/patient). Five patients received plerixafor, one from the COBE subgroup and four from the Optia subgroup. Of note, all patients with precollection CD341 counts of more than 5 3 10 6 cells/L collected more than 1.5 3 10 6 CD341 cells/kg (Fig. 3) . In the subgroup of good mobilizers, all patients from the COBE group needed only one collection and 25 of the 28 patients from the Optia group (89%) needed only one collection, the other three needed two collections.
DISCUSSION
In this retrospective study we compared clinical and collection data from peripheral stem cell collections performed with the newer Optia apheresis device to previous collections done with the COBE device. We defined two comparable groups of 41 collections each, with comparable patient demographic and clinical characteristics. There are a few studies in adult patients in the literature that compare the two apheresis machines. [12] [13] [14] [15] [16] For pediatric patients, there are only three small studies reported in the literature, one describing collections of seven low-weight patients with the Optia device, 17 the second comparing Optia collections from six low-weight patients to a historical control group of COBE collections, 18 and the third describing 19 collections from pediatric brain tumor patients, nine with the COBE and 10 with the Optia. 19 To our knowledge, our study is the largest to compare the efficiency of these two devices in pediatric patients. The main difference between the two collection groups is the reduced processed blood volumes with the Optia. Historically, at our institution, the results of the precollection peripheral CD341 counts were not available to the physician at the morning of collection as both the precollection CD341 sample and the product CD341 sample were processed together after completion of the collection. Therefore, to achieve maximal stem cell yields, our institutional practice was to process 6 3 TBVs in all patients. After initially utilizing the same TBV on the Optia machine we decided to change our institutional policy and aim for three to five TBVs based on available literature [17] [18] [19] and communications with other pediatric centers.
With this practice CE2 was 61% on the Optia, which compares well to the published literature and was higher than on the COBE in our hands. As we calculated the CE2 by using only precollection peripheral CD341 counts (CE2) assuming a stable peripheral CD341 level throughout the procedure, reduction of peripheral CD341 counts during the collection procedure and the decreased collection time may have contributed to this. 10, 11 The significantly smaller processed blood volumes translated into significantly shorter procedure times, a valuable advantage especially in the pediatric population 
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where the prolonged collection procedure can be more challenging. Moreover, smaller processed blood volumes exposed the patients to significantly lower amounts of anticoagulant and decreased the risk of electrolyte imbalances. Indeed, even with protocol-based electrolyte replacement therapy we could demonstrate a significantly lower calcium and magnesium decrease after collections with the Optia, which contributed to the lower processed ACD.
Optia product volumes were larger than the COBE product volumes. This is most likely due to the difference in chase and flush volumes. The Optia collection chamber requires a 16-mL chase and 4-mL flush, whereas COBE only requires a 5-mL chase and a 5-mL flush into the collect bag.
In our study we had a group of 24 low-weight collections of children less than 15 kg, 12 with the Optia and 12 with the COBE. Collections of low-weight children are shorter, as they process smaller blood volumes. However, in these collections blood priming of the machine is done, which prolongs the procedure time, and the flow rate of the collection is restricted by the patient weight and tolerance of inlet flow. Interestingly, although there was a significant difference between the low-weight COBE and Optia groups with respect to the processed blood volumes, the mean runtimes of the groups were similar, as opposed to shorter Optia runtimes with the medium-and heavy-weight groups (Fig.  2) . This can be explained by the longer process time in between chamber collections with the Optia machine, which balances the smaller blood volumes that are processed, with less volume difference in smaller patients. Cherqaoui and colleagues 18 have demonstrated even longer apheresis durations with the Optia in low-weight children compared to COBE collections. The calculated CR shows a correlation between the precollection peripheral CD341 cell count and the collection yield (product CD341/kg), as has been shown previously. 20 The significantly lower calculated ratio in the Optia group is not surprising, since the less volume processed for comparable precollection cell counts results in better CE2 but at the same time lesser yield (product CD341 cells/kg). The advantage of processing larger blood volumes is higher product cell counts/kg, and there is a balance between the CE2, which drops with larger volumes and the CR. We found that the Optia is as efficient as the COBE in patients who are poor mobilizers with a trend toward higher CE2 and fewer collection days in the Optia group. Almost all collections from the group of good mobilizers succeeded in achieving a sufficient CD341 collection within 1 day. This correlates with previous findings 21 and it may be concluded from these findings that a threshold of 20 3 10 6 cells/L is a good precollection estimation for a successful 1-day collection. Moreover, we could demonstrate that even lower counts of 5 3 10 6 to 20 3 10 6 cells/ L are sufficient numbers of cells when multiple collections were performed. However, the clinical decision of whether to attempt a collection procedure on a poor mobilizer should also take into account the higher DMSO reinfusion burden after multiple collection procedures or if attempting to concentrate the product, the risk of losing cells through additional cell manipulations. Several limitations of our study are worth noting. First, this is a retrospective study comparing sequential collection procedures performed with the two devices. Although the two groups were comparable in respect to disease, age, and so forth, no randomization or pairing was utilized for this study. Second, the collection procedures, especially with the manual COBE device, are user dependent and vary with the experience and preferences of the specific operator performing the procedure. Moreover, there is a learning curve especially in the beginning with every new machine. Finally, our sample size was relatively small and outcomes that were not significantly different between the groups may reflect lack of power.
The main difference between the two devices is the unique optical detection technology for automated interface management in the new Optia device as opposed to the manual interface management of the former COBE device. This automated interface in Optia gives the operator an accurate, real-time view of the current state of the collection. Another unique quality of the Optia device is the secondary separation in the chamber according to size, which separates the PLTs from the MNC to return to the patient. 22 However, in our hands this did not translate into a significant advantage in regard to the decrease in PLTs during the procedures in our study, as opposed to Cherqaoui and colleagues 16 who have demonstrated an advantage with the Optia in this respect in low-weight children.
Another advantage of the Optia device is the smaller extracorporeal volume compared to the COBE device, 242 mL versus approximately 300 mL of blood volume, which is drawn from the patient into the apheresis machine at the initiation of the procedure. Blood priming is done to prevent significant hemodynamic imbalances and in our unit we prime the Optia device with blood in cases with low-weight patients where the extracorporeal volume exceeds 15% of the patient TBV. In comparison, with the COBE device we had to prime the machine with blood in cases where the extracorporeal blood volumes exceeded 10% of the TBV. In conclusion, in our experience with the new Optia device for PBSC collections in pediatric patients, we have managed to collect comparable amounts of stem cells by processing significantly smaller blood volumes in significantly shorter procedure times compared to the previous COBE collections and with significantly less calcium and magnesium imbalance. The Optia apheresis device appears to be as safe as, and more efficient than, the former COBE device. More conclusions may be drawn in the future as more experience with the new device will be gained.
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